United Therapeutics CorporationUTHRNASDAQ
LOADING
|||
EPS Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
12.68%
↓ 66% below average
Average (39q)
37.43%
Historical baseline
Range
High:1184.09%
Low:-854.67%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 12.68% |
| Q2 2025 | -4.46% |
| Q1 2025 | 6.53% |
| Q4 2024 | -2.74% |
| Q3 2024 | 10.70% |
| Q2 2024 | -3.99% |
| Q1 2024 | 41.13% |
| Q4 2023 | -19.09% |
| Q3 2023 | 3.25% |
| Q2 2023 | 6.35% |
| Q1 2023 | 80.56% |
| Q4 2022 | -41.34% |
| Q3 2022 | 103.73% |
| Q2 2022 | -52.09% |
| Q1 2022 | 102.01% |
| Q4 2021 | -31.22% |
| Q3 2021 | -5.97% |
| Q2 2021 | 511.11% |
| Q1 2021 | -71.62% |
| Q4 2020 | -42.49% |
| Q3 2020 | 58.85% |
| Q2 2020 | -22.61% |
| Q1 2020 | 161.67% |
| Q4 2019 | -60.26% |
| Q3 2019 | -35.47% |
| Q2 2019 | 141.34% |
| Q1 2019 | -854.67% |
| Q4 2018 | -38.52% |
| Q3 2018 | -39.15% |
| Q2 2018 | -29.03% |
| Q1 2018 | 1184.09% |
| Q4 2017 | -93.09% |
| Q3 2017 | 609.60% |
| Q2 2017 | -131.17% |
| Q1 2017 | 53.64% |
| Q4 2016 | -30.40% |
| Q3 2016 | -19.35% |
| Q2 2016 | -10.40% |
| Q1 2016 | 126.64% |
| Q4 2015 | -77.55% |